FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667045> ?p ?o ?g. }

• W4385667045 endingPage "e0578580" @default.
• W4385667045 startingPage "e0578580" @default.
• W4385667045 abstract "Topic: 16. Myeloproliferative neoplasms - Clinical Background: Myelofibrosis (MF) is characterized by bone marrow (BM) fibrosis, splenomegaly and cytopenias. Progressive BM fibrosis results from aberrant megakaryopoiesis and proinflammatory cytokine expression, processes that are regulated by BET protein-mediated expression of genes. The current standard of care for MF is treatment with Janus kinase inhibitors (JAKis) such as ruxolitinib (RUX). However, unmet need persists due to the limited depth and durability of responses with JAKi monotherapy, high rates of discontinuation and toxicities (Tefferi A. Am J Hematol 2021;96(1):145–162). Pelabresib (CPI-0610; PELA) is an oral, small-molecule, investigational BET inhibitor that downregulates NF-κB signaling and other genes involved in MF disease pathways. PELA is under investigation as monotherapy and in combination with RUX in pts with MF in the ongoing, open-label Phase 2 MANIFEST study (NCT02158858). Aims: To present updated results from Arm 2 of the MANIFEST study on the efficacy and safety of PELA as ‘add-on’ to ongoing RUX in pts with suboptimal/lost response to RUX. Methods: Pts received oral PELA 125 mg QD in 21-day cycles combined with continuous oral RUX (at dose taken at time of screening). Pts in Arm 2 are stratified as transfusion dependent (TD) and nontransfusion dependent (non-TD). The primary endpoints are conversion from TD to transfusion independence (TI) in the TD cohort and ≥35% reduction in spleen volume from baseline (BL; SVR35) at Wk 24 in the non-TD cohort. Secondary endpoints include ≥50% total symptom score reduction from BL (TSS50) per MF Symptom Assessment Form v4.0 at Wk 24. Durability of responses, Hb changes, BM biopsies and safety were evaluated. Results: At data cutoff (29 July 2022), 87 pts (TD cohort = 58; non-TD cohort = 29) received PELA as add-on to RUX. Mean (SD) age was 68 (9) years; 8%, 63% and 29% pts were DIPSS Int-1, Int-2 or high risk, respectively. Pts who did not reach Wk 24 were counted as nonresponders for SVR35 and TSS50. Median treatment duration for PELA was 13.0 (range 0.25–65.4) mths. At Wk 24, 17% (15/86) of evaluable pts had SVR35 (Figure). SVR35 at any time was reported in 31% (27/86) of pts. At Wk 24, 26% (22/86) of pts had ≥25% reduction in spleen volume from BL. A total of 21% (18/86) and 19% (16/86) of pts had SVR35 response at Wk 48 and 60, respectively. Median spleen volume reduction was –17% at Wk 24. Durable (up to Wk 60) spleen volume reductions were observed (Figure). TD to TI conversion rate was 36.8% (14/38). Median TI duration was 37 wks (range 15–192). In the non-TD cohort, 24% (7/29) of pts had a Hb response (mean Hb increase of ≥1.5 g/dL from baseline without transfusions over 12 wks). TSS50 at Wk 24 was 38% (32/85) overall. A total of 55% (47/85) of pts had TSS50 at any time. Median TSS reduction was 48% at Wk 24. BM fibrosis improvement by ≥1 grade was observed in 26% of pts after 24 wks by central pathology review; 54% of pts maintained the improvement at the next available assessment or longer and 35% had ≥1 grade improvement at any time (best response). The two most common hematologic TEAEs of any grade were thrombocytopenia in 54% (Grade ≥3: 33%), and anemia in 30% (Grade ≥3: 23%) pts. A total of 26 pts (30%) reported TEAEs that led to PELA discontinuation. Serious AEs in ≥3 pts were anemia (7 pts) and pneumonia (6 pts). Conclusion: Treatment with PELA as add-on to RUX in pts with a suboptimal/lost response to RUX monotherapy resulted in durable and deepening splenic and symptom responses, and was generally well tolerated. Transfusion independence was achieved in 36.8% of pts, and improvement in BM fibrosis, as a marker of disease modification, was observed in 35% of pts.Keywords: Myeloproliferative disorder, Inhibitor, Myelofibrosis" @default.
• W4385667045 created "2023-08-09" @default.
• W4385667045 creator A5004066566 @default.
• W4385667045 creator A5008304075 @default.
• W4385667045 creator A5008609620 @default.
• W4385667045 creator A5011529063 @default.
• W4385667045 creator A5013173470 @default.
• W4385667045 creator A5016229715 @default.
• W4385667045 creator A5039057642 @default.
• W4385667045 creator A5046772202 @default.
• W4385667045 creator A5046827092 @default.
• W4385667045 creator A5047764826 @default.
• W4385667045 creator A5065098368 @default.
• W4385667045 creator A5067214379 @default.
• W4385667045 creator A5072336042 @default.
• W4385667045 creator A5077063317 @default.
• W4385667045 creator A5083235365 @default.
• W4385667045 creator A5085521139 @default.
• W4385667045 date "2023-08-01" @default.
• W4385667045 modified "2023-10-18" @default.
• W4385667045 title "P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS" @default.
• W4385667045 doi "https://doi.org/10.1097/01.hs9.0000970976.05785.80" @default.
• W4385667045 hasPublicationYear "2023" @default.
• W4385667045 type Work @default.
• W4385667045 citedByCount "0" @default.
• W4385667045 crossrefType "journal-article" @default.
• W4385667045 hasAuthorship W4385667045A5004066566 @default.
• W4385667045 hasAuthorship W4385667045A5008304075 @default.
• W4385667045 hasAuthorship W4385667045A5008609620 @default.
• W4385667045 hasAuthorship W4385667045A5011529063 @default.
• W4385667045 hasAuthorship W4385667045A5013173470 @default.
• W4385667045 hasAuthorship W4385667045A5016229715 @default.
• W4385667045 hasAuthorship W4385667045A5039057642 @default.
• W4385667045 hasAuthorship W4385667045A5046772202 @default.
• W4385667045 hasAuthorship W4385667045A5046827092 @default.
• W4385667045 hasAuthorship W4385667045A5047764826 @default.
• W4385667045 hasAuthorship W4385667045A5065098368 @default.
• W4385667045 hasAuthorship W4385667045A5067214379 @default.
• W4385667045 hasAuthorship W4385667045A5072336042 @default.
• W4385667045 hasAuthorship W4385667045A5077063317 @default.
• W4385667045 hasAuthorship W4385667045A5083235365 @default.
• W4385667045 hasAuthorship W4385667045A5085521139 @default.
• W4385667045 hasBestOaLocation W43856670451 @default.
• W4385667045 hasConcept C126322002 @default.
• W4385667045 hasConcept C143998085 @default.
• W4385667045 hasConcept C2776112149 @default.
• W4385667045 hasConcept C2778715236 @default.
• W4385667045 hasConcept C2780007613 @default.
• W4385667045 hasConcept C2780076729 @default.
• W4385667045 hasConcept C71924100 @default.
• W4385667045 hasConcept C72563966 @default.
• W4385667045 hasConcept C90924648 @default.
• W4385667045 hasConceptScore W4385667045C126322002 @default.
• W4385667045 hasConceptScore W4385667045C143998085 @default.
• W4385667045 hasConceptScore W4385667045C2776112149 @default.
• W4385667045 hasConceptScore W4385667045C2778715236 @default.
• W4385667045 hasConceptScore W4385667045C2780007613 @default.
• W4385667045 hasConceptScore W4385667045C2780076729 @default.
• W4385667045 hasConceptScore W4385667045C71924100 @default.
• W4385667045 hasConceptScore W4385667045C72563966 @default.
• W4385667045 hasConceptScore W4385667045C90924648 @default.
• W4385667045 hasIssue "S3" @default.
• W4385667045 hasLocation W43856670451 @default.
• W4385667045 hasLocation W43856670452 @default.
• W4385667045 hasOpenAccess W4385667045 @default.
• W4385667045 hasPrimaryLocation W43856670451 @default.
• W4385667045 hasRelatedWork W2547101781 @default.
• W4385667045 hasRelatedWork W2731573311 @default.
• W4385667045 hasRelatedWork W3120572889 @default.
• W4385667045 hasRelatedWork W3141140978 @default.
• W4385667045 hasRelatedWork W3165639147 @default.
• W4385667045 hasRelatedWork W4207016570 @default.
• W4385667045 hasRelatedWork W4221100544 @default.
• W4385667045 hasRelatedWork W4251586583 @default.
• W4385667045 hasRelatedWork W4283399567 @default.
• W4385667045 hasRelatedWork W4385344054 @default.
• W4385667045 hasVolume "7" @default.
• W4385667045 isParatext "false" @default.
• W4385667045 isRetracted "false" @default.
• W4385667045 workType "article" @default.